Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- All Concerned Parties Should Cooperate to Improve Business Practices: Mr Matsutani
January 21, 2008
- Health Net and Med-Solution to Form Alliance for Clinical Imaging Studies
January 21, 2008
- PMDA to Expand Review System for Generics, OTC Drugs: Chief Executive Miyajima
January 21, 2008
- MEDICAL DEVICE NEWS IN BRIEF
January 21, 2008
- Korosho to Expand System to Determine Market Trend for Generics
January 21, 2008
- Reimbursement Prices for 5 Chemotherapy Regimens under DPC System to Be Reconsidered
January 21, 2008
- Nichi-Iko Improves Distribution, Production Systems to Ensure Overnight Deliveries
January 21, 2008
- Int'l Cooperation Needed to Eliminate Counterfeit Drugs: Prof. Kimura
January 21, 2008
- Generics Market Estimated to Reach \338 Billion in 2009: Fuji Keizai
January 21, 2008
- Salagen Improves QOL of Patients with Sjogren's Syndrome
January 21, 2008
- Teva to See Its First NHI Price Listing in 2008
January 14, 2008
- TOPICS／Novartis Pharma to Introduce New System to Improve MR Competence
January 14, 2008
- BUSINESS NEWS IN BRIEF
January 14, 2008
- MEDICAL DEVICE NEWS IN BRIEF
January 14, 2008
- Blopress Maintains No. 1 Position: Top 100 Drugs Ranking
January 14, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 14, 2008
- NEW PRODUCTS
January 14, 2008
- Pfizer to Conduct PII Study on Glaucoma Treatment from NicOx
January 14, 2008
- AstraZeneca Aims at Sales of \33 Bil. with Drugs for Breast Cancer in 2008
January 14, 2008
- Standard Forms Completed for Clinical Trial Documents
January 14, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…